

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

|   |   |  |
|---|---|--|
| 1. Name and Address of Reporting Person*<br><u>Longitude Venture Partners L.P.</u><br><br>(Last) (First) (Middle)<br>800 EL CAMINO REAL<br>SUITE 220<br><br>(Street)<br>MENLO PARK CA 94025<br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>CORCEPT THERAPEUTICS INC [ CORT ]</u> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><br><input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br><br>Officer (give title below) Other (specify below) |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br>03/05/2014                          |  |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)  |   |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                         | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                   |   |  |   |
| Common Stock                    | 03/05/2014                           |  | S                              |   | 70,063  | D          | \$4.0098 <sup>(1)</sup> | 13,175,781 <sup>(2)</sup>   | D <sup>(3)</sup>   |   |
| Common Stock                    | 03/05/2014                           |  | S                              |   | 1,404   | D          | \$4.0098 <sup>(1)</sup> | 186,325 <sup>(4)</sup>  | D <sup>(5)</sup>   |   |
| Common Stock                    | 03/06/2014                           |  | S                              |   | 164,800   | D          | \$4.0007 <sup>(6)</sup> | 13,010,981 <sup>(2)</sup>   | D <sup>(3)</sup>   |   |
| Common Stock                    | 03/06/2014                           |  | S                              |   | 3,303   | D          | \$4.0007 <sup>(6)</sup> | 183,022 <sup>(4)</sup>  | D <sup>(5)</sup>   |   |
| Common Stock                    | 03/07/2014                           |  | S                              |   | 10,225  | D          | \$4                     | 13,000,756 <sup>(2)</sup>   | D <sup>(3)</sup>   |   |
| Common Stock                    | 03/07/2014                           |  | S                              |   | 205   | D          | \$4                     | 182,817 <sup>(4)</sup>  | D <sup>(5)</sup>   |   |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date |   |  |  |   |  |

1. Name and Address of Reporting Person\*  
Longitude Venture Partners L.P.  
  
 (Last) (First) (Middle)  
 800 EL CAMINO REAL  
 SUITE 220  
  
 (Street)  
 MENLO PARK CA 94025  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Longitude Capital Associates, L.P.  
  
 (Last) (First) (Middle)  
 800 EL CAMINO REAL  
 SUITE 220  
  
 (Street)  
 MENLO PARK CA 94025  
  
 (City) (State) (Zip)

|  |         |          |
|--|---------|----------|
| (City)   | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*                               |         |          |
| <a href="#">Longitude Capital Partners, LLC</a>                        |         |          |
| (Last)   | (First) | (Middle) |
| 800 EL CAMINO REAL<br>SUITE 220  |         |          |
| (Street)   |         |          |
| MENLO PARK   | CA      | 94025    |
| (City)   | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*                               |         |          |
| <a href="#">Tammenoms Bakker Juliet</a>                                |         |          |
| (Last)   | (First) | (Middle) |
| LONGITUDE CAPITAL MANAGEMENT CO., LLC<br>800 EL CAMINO REAL, SUITE 220 |         |          |
| (Street)   |         |          |
| MENLO PARK   | CA      | 94025    |
| (City)   | (State) | (Zip)    |

**Explanation of Responses:**

1. Reflects sales of common stock executed in multiple transactions at prices ranging from \$4.00 to \$4.07. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
2. Does not include warrants held by Longitude Venture Partners, L.P. ("LVP") to purchase 3,091,479 shares of common stock.
3. Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital") and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
4. Does not include warrants held by Longitude Capital Associates, L.P. ("LCA") to purchase 26,583 shares of common stock.
5. Reflects transactions and holdings of shares of common stock held of record by LCA. This report is jointly filed by LCA, Longitude Capital and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
6. Reflects sales of common stock executed in multiple transactions at prices ranging from \$4.00 to \$4.01. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.

**Remarks:**

\*\*\*All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan\*\*\*

[/s/ Juliet Tammenoms Bakker,](#)  
[as managing member of](#)  
[Longitude Capital Partners,](#)      [03/07/2014](#)  
[LLC, as general partner of](#)  
[Longitude Venture Partners,](#)  
[L.P.](#)

[/s/ Juliet Tammenoms Bakker,](#)  
[as managing member of](#)  
[Longitude Capital Partners,](#)      [03/07/2014](#)  
[LLC, as general partner of](#)  
[Longitude Capital Associates,](#)  
[L.P.](#)

[/s/ Juliet Tammenoms Bakker,](#)      [03/07/2014](#)  
[as managing member](#)

[/s/ Juliet Tammenoms Bakker](#)      [03/07/2014](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.